[{"id":"fd69b3ec-1305-4dd1-87d3-4b0c8f4a1b9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661384","created_at":"2025-06-07T14:44:26.057Z","updated_at":"2025-06-07T14:44:26.057Z","phase":"Phase 1","brief_title":"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma","source_id_and_acronym":"NCT04661384","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":"","alterations":" ","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/17/2025","primary_completion_date":" 11/17/2025","study_txt":" Completion: 11/17/2025","study_completion_date":" 11/17/2025","last_update_posted":"2025-06-03"},{"id":"6076406a-9463-43ad-ba76-13f9a5a2bd1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445288","created_at":"2021-01-18T05:59:39.581Z","updated_at":"2025-02-25T13:39:05.076Z","phase":"","brief_title":"Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","source_id_and_acronym":"NCT01445288","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • TNFA","pipe":"","alterations":" ","tags":["VEGFA • TNFA"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/05/2006","start_date":" 12/05/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"2d640cff-e8d0-459a-ae6a-92adad2804d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173950","created_at":"2022-04-11T23:54:29.961Z","updated_at":"2025-02-25T14:07:01.366Z","phase":"Phase 2","brief_title":"Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers","source_id_and_acronym":"NCT03173950","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCOR • FOXR2","pipe":"","alterations":" ","tags":["BCOR • FOXR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 07/13/2017","start_date":" 07/13/2017","primary_txt":" Primary completion: 07/15/2025","primary_completion_date":" 07/15/2025","study_txt":" Completion: 07/15/2026","study_completion_date":" 07/15/2026","last_update_posted":"2025-02-18"},{"id":"b727510f-e4dd-45d1-a75b-a7fd6215444a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598244","created_at":"2021-01-18T17:41:26.385Z","updated_at":"2025-02-25T14:15:11.442Z","phase":"Phase 1","brief_title":"Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors","source_id_and_acronym":"NCT03598244","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"a3330799-3a3c-4c3b-bada-534a183f734f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05382338","created_at":"2022-05-19T11:56:15.604Z","updated_at":"2025-02-25T15:12:50.886Z","phase":"Phase 3","brief_title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","source_id_and_acronym":"NCT05382338","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • GLI2","pipe":" | ","alterations":" TP53 wild-type","tags":["MYCN • GLI2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • mesna"],"overall_status":"Suspended","enrollment":" Enrollment 225","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/20/2027","primary_completion_date":" 12/20/2027","study_txt":" Completion: 12/20/2027","study_completion_date":" 12/20/2027","last_update_posted":"2025-02-13"},{"id":"b3fcd5d4-2376-4a44-a782-f5af77183569","acronym":"LEAHRN","url":"https://clinicaltrials.gov/study/NCT02724579","created_at":"2021-01-18T13:20:08.012Z","updated_at":"2025-02-25T15:10:23.410Z","phase":"Phase 2","brief_title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","source_id_and_acronym":"NCT02724579 - LEAHRN","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["MYCN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 11/17/2017","start_date":" 11/17/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-13"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"67575df3-fe79-49cd-97ab-2aa59bfde6c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02359565","created_at":"2021-01-18T11:13:52.172Z","updated_at":"2025-02-25T16:58:45.335Z","phase":"Phase 1","brief_title":"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma","source_id_and_acronym":"NCT02359565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2025-02-03"},{"id":"b02d7446-9c2e-44de-aefb-87c2ab738292","acronym":"DOMINO START","url":"https://clinicaltrials.gov/study/NCT04081701","created_at":"2021-01-18T19:59:05.539Z","updated_at":"2025-02-25T15:43:40.367Z","phase":"Phase 4","brief_title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","source_id_and_acronym":"NCT04081701 - DOMINO START","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 12/31/2038","primary_completion_date":" 12/31/2038","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-12-19"},{"id":"b59b27f1-de71-4f26-8ce2-01742271e9ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161519","created_at":"2023-12-08T15:15:31.906Z","updated_at":"2024-07-02T16:34:38.055Z","phase":"Phase 1/2","brief_title":"PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications","source_id_and_acronym":"NCT06161519","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLX038"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 11/14/2028","primary_completion_date":" 11/14/2028","study_txt":" Completion: 11/14/2033","study_completion_date":" 11/14/2033","last_update_posted":"2024-06-05"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"d9dd8a9e-c9dc-461e-aece-5bc7f49d536e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03709680","created_at":"2021-11-09T18:05:08.609Z","updated_at":"2024-07-02T16:35:02.132Z","phase":"Phase 1/2","brief_title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","source_id_and_acronym":"NCT03709680","lead_sponsor":"Pfizer","biomarkers":" EWSR1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2024-05-22"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"6ab65671-28fd-4a23-bc0c-3d5205104b75","acronym":"PRiME","url":"https://clinicaltrials.gov/study/NCT03299309","created_at":"2021-01-18T16:18:00.321Z","updated_at":"2024-07-02T16:35:04.405Z","phase":"Phase 1","brief_title":"PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma","source_id_and_acronym":"NCT03299309 - PRiME","lead_sponsor":"Daniel Landi","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/29/2018","start_date":" 06/29/2018","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-10"},{"id":"15e4b775-392e-472a-b90f-3881d6fdb3cc","acronym":"CSAγδTBMG","url":"https://clinicaltrials.gov/study/NCT06396481","created_at":"2024-05-04T04:25:31.336Z","updated_at":"2024-07-02T16:35:06.525Z","phase":"Phase 1","brief_title":"Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma","source_id_and_acronym":"NCT06396481 - CSAγδTBMG","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-05-02"},{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"945e49ad-157e-4566-89d3-6b4ba4498abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04696029","created_at":"2021-01-19T20:49:35.193Z","updated_at":"2024-07-02T16:35:10.980Z","phase":"Phase 2","brief_title":"DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma","source_id_and_acronym":"NCT04696029","lead_sponsor":"Giselle Sholler","biomarkers":" TP53 • MYC • MYCN","pipe":" | ","alterations":" TP53 mutation • MYCN amplification • TP53 amplification","tags":["TP53 • MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MYCN amplification • TP53 amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-04-08"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"},{"id":"413fd329-dd85-45a6-b07c-a0fee98c2f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT04743661","created_at":"2021-02-08T13:52:25.106Z","updated_at":"2024-07-02T16:35:12.204Z","phase":"Phase 2","brief_title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","source_id_and_acronym":"NCT04743661","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 10/30/2029","primary_completion_date":" 10/30/2029","study_txt":" Completion: 10/30/2030","study_completion_date":" 10/30/2030","last_update_posted":"2024-03-29"},{"id":"100df7a9-71f2-4628-80e7-56222961276b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02962167","created_at":"2021-01-19T13:11:56.112Z","updated_at":"2024-07-02T16:35:13.720Z","phase":"Phase 1","brief_title":"Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT","source_id_and_acronym":"NCT02962167","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MV-NIS"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 02/22/2017","start_date":" 02/22/2017","primary_txt":" Primary completion: 05/10/2023","primary_completion_date":" 05/10/2023","study_txt":" Completion: 05/10/2023","study_completion_date":" 05/10/2023","last_update_posted":"2024-03-20"},{"id":"8692edc5-36b9-41d3-83ee-d4803fca127c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05835687","created_at":"2023-04-28T15:04:55.022Z","updated_at":"2024-07-02T16:35:14.889Z","phase":"Phase 1","brief_title":"Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors","source_id_and_acronym":"NCT05835687","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B7-H3 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/27/2023","start_date":" 04/27/2023","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-03-13"}]